1616 related articles for article (PubMed ID: 17330229)
41. Is sentinel lymph node biopsy more accurate than axillary dissection for staging nodal involvement in breast cancer patients?
Marrazzo A; Taormina P; Gebbiab V; David M; Riili I; Lo Gerfo D; Casà L; Noto A
Chir Ital; 2007; 59(5):693-9. PubMed ID: 18019642
[TBL] [Abstract][Full Text] [Related]
42. Histopathologic analysis of sentinel lymph nodes in breast carcinoma.
Hsieh PP; Ho WL; Yeh DC; Liu TJ; Wu CC; Lin JH; Wang SJ
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):744-50. PubMed ID: 11076431
[TBL] [Abstract][Full Text] [Related]
43. Prognostic significance of residual breast disease and axillary node involvement for patients who had primary induction chemotherapy for advanced breast cancer.
Escobar PF; Patrick RJ; Rybicki LA; Hicks D; Weng DE; Crowe JP
Ann Surg Oncol; 2006 Jun; 13(6):783-7. PubMed ID: 16604475
[TBL] [Abstract][Full Text] [Related]
44. ICG fluorescence-guided sentinel node biopsy for axillary nodal staging in breast cancer.
Hirche C; Murawa D; Mohr Z; Kneif S; Hünerbein M
Breast Cancer Res Treat; 2010 Jun; 121(2):373-8. PubMed ID: 20140704
[TBL] [Abstract][Full Text] [Related]
45. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status.
Kuerer HM; Newman LA; Buzdar AU; Dhingra K; Hunt KK; Buchholz TA; Binkley SM; Strom EA; Ames FC; Ross MI; Feig BW; McNeese MD; Hortobagyi GN; Singletary SE
Cancer J Sci Am; 1998; 4(4):230-6. PubMed ID: 9689981
[TBL] [Abstract][Full Text] [Related]
46. Number of lymph nodes removed in sentinel lymph node-negative breast cancer patients is significantly related to patient age and tumor size: a new source of bias in morbidity assessment?
Port ER; Patil S; Stempel M; Morrow M; Cody HS
Cancer; 2010 Apr; 116(8):1987-91. PubMed ID: 20151427
[TBL] [Abstract][Full Text] [Related]
47. Clinicopathological factors and nomograms predicting nonsentinel lymph node metastases after neoadjuvant chemotherapy in breast cancer patients.
Gimbergues P; Abrial C; Durando X; Le Bouedec G; Cachin F; Penault-Llorca F; Mouret-Reynier MA; Kwiatkowski F; Maublant J; Tchirkov A; Dauplat J
Ann Surg Oncol; 2009 Jul; 16(7):1946-51. PubMed ID: 19408057
[TBL] [Abstract][Full Text] [Related]
48. Sentinel lymph node biopsy is a reliable method for lymph node evaluation in neoadjuvant chemotherapy-treated patients with breast cancer.
Koslow SB; Eisenberg RE; Qiu Q; Chen Z; Swistel A; Shin SJ
Am Surg; 2014 Feb; 80(2):171-7. PubMed ID: 24480218
[TBL] [Abstract][Full Text] [Related]
49. Feasibility of sentinel lymph node biopsy in multifocal/multicentric breast cancer.
Lo YF; Cheung YC; Hsueh S; Ho KC
Chang Gung Med J; 2009; 32(1):51-8. PubMed ID: 19292939
[TBL] [Abstract][Full Text] [Related]
50. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection.
Hwang RF; Gonzalez-Angulo AM; Yi M; Buchholz TA; Meric-Bernstam F; Kuerer HM; Babiera GV; Tereffe W; Liu DD; Hunt KK
Cancer; 2007 Aug; 110(4):723-30. PubMed ID: 17587208
[TBL] [Abstract][Full Text] [Related]
51. Influence of frozen-section analysis of sentinel lymph node and lumpectomy margin status on reoperation rates in patients undergoing breast-conservation therapy.
McLaughlin SA; Ochoa-Frongia LM; Patil SM; Cody HS; Sclafani LM
J Am Coll Surg; 2008 Jan; 206(1):76-82. PubMed ID: 18155571
[TBL] [Abstract][Full Text] [Related]
52. Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer.
Cox CE; Cox JM; White LB; Stowell NG; Clark JD; Allred N; Meyers M; Dupont E; Furman B; Minton S
Ann Surg Oncol; 2006 Apr; 13(4):483-90. PubMed ID: 16523361
[TBL] [Abstract][Full Text] [Related]
53. Factors that predict the burden of axillary disease in breast cancer patients with a positive sentinel node.
Beriwal S; Soran A; Kocer B; Wilson JW; Ahrendt GM; Johnson R
Am J Clin Oncol; 2008 Feb; 31(1):34-8. PubMed ID: 18376225
[TBL] [Abstract][Full Text] [Related]
54. Sentinel lymph node biopsy. Preferred method of axillary staging for breast cancer.
Tuttle TM
Minerva Ginecol; 2005 Jun; 57(3):293-303. PubMed ID: 16166937
[TBL] [Abstract][Full Text] [Related]
55. Sentinel node biopsy in breast cancer patients treated with neoadjuvant chemotherapy.
Tanaka Y; Maeda H; Ogawa Y; Nishioka A; Itoh S; Kubota K; Ue H; Nakatani K; Sasaguri S
Oncol Rep; 2006 Apr; 15(4):927-31. PubMed ID: 16525681
[TBL] [Abstract][Full Text] [Related]
56. Intraoperative cytologic examination of breast sentinel lymph nodes: test utility and patient impact.
Dabbs DJ; Fung M; Johnson R
Breast J; 2004; 10(3):190-4. PubMed ID: 15125743
[TBL] [Abstract][Full Text] [Related]
57. Axillary sentinel node biopsy after neoadjuvant chemotherapy.
Ozmen V; Unal ES; Muslumanoglu ME; Igci A; Canbay E; Ozcinar B; Mudun A; Tunaci M; Tuzlali S; Kecer M
Eur J Surg Oncol; 2010 Jan; 36(1):23-9. PubMed ID: 19931375
[TBL] [Abstract][Full Text] [Related]
58. Preoperative axillary ultrasound and fine-needle aspiration biopsy in the diagnosis of axillary metastases in patients with breast cancer: predictors of accuracy and future implications.
Cools-Lartigue J; Sinclair A; Trabulsi N; Meguerditchian A; Mesurolle B; Fuhrer R; Meterissian S
Ann Surg Oncol; 2013 Mar; 20(3):819-27. PubMed ID: 22972506
[TBL] [Abstract][Full Text] [Related]
59. Sentinel node biopsy after neoadjuvant chemotherapy in cytologically proven node-positive breast cancer.
Yagata H; Yamauchi H; Tsugawa K; Hayashi N; Yoshida A; Kajiura Y; In R; Matsuda N; Nakamura S
Clin Breast Cancer; 2013 Dec; 13(6):471-7. PubMed ID: 24267732
[TBL] [Abstract][Full Text] [Related]
60. Is breast cancer sentinel lymph node mapping valuable for patients in their seventies and beyond?
McMahon LE; Gray RJ; Pockaj BA
Am J Surg; 2005 Sep; 190(3):366-70. PubMed ID: 16105520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
